Furthermore, PKCε specific VHHs could in the future be developed into therapeutics against diseases such as cancer or type II diabetes, or the CDR regions of VHHs could be used to design novel peptide-based therapies against these life-threatening diseases. This evidence concerns the gene PRKCE and type 2 diabetes mellitus.